|
|
Post by peppy on Oct 14, 2016 11:21:20 GMT -5
In three weeks. Management should be more free to talk about Sanofi settlements. Perhaps news of RLS milestone. Management needs to tell us they have cash and the plan for the label/pediatric trial. Or what the hell the plan is.
The worlds dream fast acting insulin. Can you believe it?
|
|
|
|
Post by slugworth008 on Oct 14, 2016 11:25:04 GMT -5
In three weeks. Management should be more free to talk about Sanofi settlements. Perhaps news of RLS milestone. Management needs to tell us they have cash and the plan for the label/pediatric trial. Or what the hell the plan is.
The worlds dream fast acting insulin. Can you believe it?
I seriously hope this upcoming CC is rock damn solid. |
|
|
|
Post by Chris-C on Oct 14, 2016 11:45:50 GMT -5
In three weeks. Management should be more free to talk about Sanofi settlements. Perhaps news of RLS milestone. Management needs to tell us they have cash and the plan for the label/pediatric trial. Or what the hell the plan is.
The worlds dream fast acting insulin. Can you believe it?
Peppy If you are asking how it is possible that a company with such a great technology could be faced with such an improbable financial situation, I can only reply that this year, the improbable seems to rule. Somehow, Lewis Carroll got control of the world's rudder to steer us through the looking glass into a place where ordinary language is inadequate to describe what we are now experiencing. So our only practical option is to enjoy the ride in wonderment, turning to each other in amazement while repeating the question "really?". GLTAL Chris C |
|
|
|
Post by Cowgirl on Oct 14, 2016 13:30:55 GMT -5
Slugworth...
Management doesn't really care where the share price is. They run the business and do the best they can and the share price should theoretically follow.
The problem with that philosophy is that they don't appear to care about shareholders as Al Mann Foundation is largest and significantly influencing control. They have a "as long as it takes" return on investment requirement. They do as they wish.
It always was ok in the past though as Al Mann had his Mini Med money etc....but it's now all gone...and yet they continue the same philosophy. MGMT got used to just spinning tales and fending off shareholders. And they have a lot of experience with very low share prices....so next call, We've made great progress, amazing speed, users like it...but wall street doesn't care about a "good try" ...we need a partner(s).
|
|
|
|
Post by peppy on Oct 17, 2016 8:49:49 GMT -5
At 48 cents Management has some explaining to do.
The world best fast acting insulin as seen on continuous glucose monitors stock is trading at 48 cents. hmmmm
Management needs to make it an extra long conference call.
I know it sounds crazy, the continuous glucose monitors as evidence should be able to fast track afrezza. crazy, I know.
|
|
|
|
Post by dictatorsaurus on Oct 17, 2016 9:07:00 GMT -5
At 48 cents Management has some explaining to do.
The world best fast acting insulin as seen on continuous glucose monitors stock is trading at 48 cents. hmmmm
Management needs to make it an extra long conference call.
I know it sounds crazy, the continuous glucose monitors as evidence should be able to fast track afrezza. crazy, I know.
Fast track an already approved drug? hmm... How many times have we been in this position before where we anticipate a CC only to have management prove time and time again their incompetency. How many times have we praised their silence assuming there is some secretive great plan in the making, only to have the CEO embarrass himself and the shareholders. Each time I cross my fingers and hope for something different, but the only consistent trend I am noticing is the management's inability to deliver. Best thing Matt ever did was hire Mike C. But mike is only one man part of a large complex machine. Before the devoted loyals with unconditional love pounce and critique my statement, take a look at the chart today. 48 glorious cents. Not enough to buy you small sized coffee at the discount gas station. |
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Oct 17, 2016 9:14:22 GMT -5
At 48 cents Management has some explaining to do.
The world best fast acting insulin as seen on continuous glucose monitors stock is trading at 48 cents. hmmmm
Management needs to make it an extra long conference call.
I know it sounds crazy, the continuous glucose monitors as evidence should be able to fast track afrezza. crazy, I know. CGM idea not crazy. I told MNKD to set up a trial with largest health insurers and run it for 90 days or so. A1c every month or so to demonstrate how fast and large the A1c drops would be. Then, the insurance cos could decide for themselves by looking at data obtained from their own patient population. Can you imagine if United Health and 2-3 others did this for 100 patients, and had Afrezzauser type results and expanded to 500 patients and see if data continues to be as strong and initial trial where we would have been? |
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Oct 17, 2016 9:18:41 GMT -5
The next CC will be just like the last bunch of CC's. If anything material was happening, we'd find out about it long before the CC unless the timing just happened to work out that way. What's more concerning is what might happen right after the CC. They have to raise cash and if we don't hear anything over the next 3 weeks, I don't believe the CC will be a "fun" event. The holidays are coming and raising cash around this time of year is very problematic. So, they get something done now and extend the runway or they wait till early 2017, which I don't see how that would be possible pending a cash infusion from say RLS or SNY.
|
|
|
|
Post by matt on Oct 17, 2016 9:52:29 GMT -5
The holidays are coming and raising cash around this time of year is very problematic. So, they get something done now and extend the runway or they wait till early 2017, which I don't see how that would be possible pending a cash infusion from say RLS or SNY. That comment is exactly correct; if you try to play chicken with the financial market the market will win. The company has to raise money now and they cannot bet the future on concluding discussions on cash payments from RLS or Sanofi in time to avoid an insolvency event. In the world of every man for himself, both RLS and Sanofi have an incentive to stretch out the process as long as possible because that gives them maximum leverage over MNKD and the longer it goes on the more leverage they have.
The problem is that Matt may have waited too long to pull the trigger. Doing a significant raise at 46 cents may not be possible regardless of the terms.
|
|
|
|
Post by mnkdfann on Oct 17, 2016 9:52:33 GMT -5
Is the actual date of the call out yet? I see Yahoo Finance estimates it as around Nov 7 - 11.
If it is on the 7th, 8th, or 9th, I would take it as a bad timing sign (i.e. hoping to get lost in the associated election day circus).
|
|
|
|
Post by Cowgirl on Oct 17, 2016 10:04:15 GMT -5
The reason for the price decline so quickly from 60 cents may be the reverse split in the works. I suspect MNKD will have a small nugget of something unexpected that could be a small positive but it won't be
much. This is a disaster as the CEO always promised partners in pain management, international partners to beef up volumn in Conn., some Sanofi settlement etc. He became a master of the smoke and mirrors all these years as they had Al Mann's money to let them "go it alone - you other shareholders are just along for the ride - follow us and you'll be rewarded". Now, the game is over - they have nothing except 300 scripts a week - building a bit but not earth moving from a dedicated sales force covering 75% of the market place. Al Mann's money is GONE. Where are the partners bringing us money Matt? (No where to be found)
|
|
|
|
Post by silentknight on Oct 17, 2016 10:08:14 GMT -5
I only see two options to keep us afloat.
1) MNKD announces the receipt cash from either tapping the ATM, milestone payment from RLS, or from a Sanofi settlement. Anything garnered from this will likely be only enough to fund another 1-2 months of cash burn and would do nothing to provide a solution to MNKD's financial woes. I also don't think any of these have happened or will. ATM use at this point is pointless as you're selling shares at .46 cents.
2) MNKD announces a reverse split and dilution. Even at at 10-1 reverse split, the share price only goes to 4.60 but that would give MNKD a better platform to offer a secondary. It's also likely the only way we see MNKD stay into Nasdaq compliance. We are 20% into the delisting window and the stock is still falling like a rock with no turnaround in sight. As much as I hate to see this, I honestly don't see any other way for MNKD to stay upright without a R/S and dilution.
Either way, the company needs to answer the uncertainty one way or another. Scripts are not picking up fast enough to keep the company in operation and while they might need more time, it's time they don't have.
|
|
|
|
Post by seanismorris on Oct 17, 2016 10:36:48 GMT -5
I'm not seeing a settlement happening. A settlement was based on MannKinds sales team significantly outperforming Sanofi's, thereby showing Sanofi didn't put enough effort in bringing Afrezza to market. That hasn't happened, therefor no money.
This CC is going to be bad, very bad...
Even with a better Label, they're going to have difficulty convincing anyone that Afrezza is anything but a niche product. And, a money loosing one at that.
If Afrezza is a niche, that suggest the value of TS isn't what we think it is. Options are limited, we need a miracle.
I can't even trade this. Short is the only position that makes sense and that's not my style.
|
|
|
|
Post by prvs on Oct 17, 2016 16:15:23 GMT -5
I think Matt will spend more time talking about all the strategies they are using to gain a customer base. I also think he will announce a r/s as that is what makes the most sense. After getting to this point by being dragged kicking and screaming, I see that this would be best for the stock holders and the company. Even if my 90k shares become 9k shares, the company will survive and will gain some time. Better than bk any day
|
|
|
|
Post by mannmade on Oct 17, 2016 16:29:20 GMT -5
There is another possibility not mentioned in this thread... (and I am not speculating on whether or not it may happen, rather just offering up as not mentioned here). Mnkd could do an Epihale deal say for $20m to $30m upfront and an advance (loan) against future royalties for $30m or so.
This is a product that should be available for retail by early 2018 that uses an approved API and technosphere that has already been approved by the FDA so will likely be able to expedite approval. Not to mention that any number of pharma's might be interested in it given the current headlines and mood of Congress as I have stated previously on this subject.
And this would not require any dilution...
|
|
